Thomas Capozza, MD, FACP

Vice President, Clinical Development
Intercept Pharmaceuticals, Inc.

Poster(s):

• (185) Real-world analysis of treatment patterns and healthcare resource utilization among patients with alcohol-associated hepatitis from 2016 to 2024
  Wednesday, October 29, 2025